Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052.

Palumbo PJ, Wilson EA, Piwowar-Manning E, McCauley M, Gamble T, Kumwenda N, Makhema J, Kumarasamy N, Chariyalertsak S, Hakim JG, Hosseinipour MC, Melo MG, Godbole SV, Pilotto JH, Grinsztejn B, Panchia R, Chen YQ, Cohen MS, Eshleman SH, Fogel JM.

PLoS One. 2017 May 8;12(5):e0177281. doi: 10.1371/journal.pone.0177281. eCollection 2017.

2.

Virologic outcomes in early antiretroviral treatment: HPTN 052.

Eshleman SH, Wilson EA, Zhang XC, Ou SS, Piwowar-Manning E, Eron JJ, McCauley M, Gamble T, Gallant JE, Hosseinipour MC, Kumarasamy N, Hakim JG, Kalonga B, Pilotto JH, Grinsztejn B, Godbole SV, Chotirosniramit N, Santos BR, Shava E, Mills LA, Panchia R, Mwelase N, Mayer KH, Chen YQ, Cohen MS, Fogel JM.

HIV Clin Trials. 2017 May;18(3):100-109. doi: 10.1080/15284336.2017.1311056. Epub 2017 Apr 7.

PMID:
28385131
3.

Medical Education Partnership Initiative in Zimbabwe: partnerships for transformation.

Hakim JG, Barry M, Matenga J, Cowan F, Campbell TB.

Lancet Glob Health. 2017 Feb;5(2):e143-e144. doi: 10.1016/S2214-109X(17)30005-0. No abstract available.

4.

Adult Hematology and Clinical Chemistry Laboratory Reference Ranges in a Zimbabwean Population.

Samaneka WP, Mandozana G, Tinago W, Nhando N, Mgodi NM, Bwakura-Dangarembizi MF, Munjoma MW, Gomo ZA, Chirenje ZM, Hakim JG.

PLoS One. 2016 Nov 3;11(11):e0165821. doi: 10.1371/journal.pone.0165821. eCollection 2016.

5.

Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy.

Singini I, Campbell TB, Smeaton LM, Kumarasamy N, La Rosa A, Taejareonkul S, Safren SA, Flanigan TP, Hakim JG, Hughes MD; ACTG A5175/PEARLS Study Team.

HIV Clin Trials. 2016 Jul 29:1-8. [Epub ahead of print]

PMID:
27472067
6.

Antiretroviral Therapy for the Prevention of HIV-1 Transmission.

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Cottle L, Zhang XC, Makhema J, Mills LA, Panchia R, Faesen S, Eron J, Gallant J, Havlir D, Swindells S, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano DD, Essex M, Hudelson SE, Redd AD, Fleming TR; HPTN 052 Study Team.

N Engl J Med. 2016 Sep 1;375(9):830-9. doi: 10.1056/NEJMoa1600693. Epub 2016 Jul 18.

7.

Manuscript title: Facilitators and barriers to cotrimoxazole prophylaxis among HIV exposed babies: a qualitative study from Harare, Zimbabwe.

Sibanda EL, Bernays S, Weller IV, Hakim JG, Cowan FM.

BMC Public Health. 2015 Aug 15;15:784. doi: 10.1186/s12889-015-2136-0.

8.

A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings.

Erlandson KM, Taejaroenkul S, Smeaton L, Gupta A, Singini IL, Lama JR, Mngqibisa R, Firnhaber C, Cardoso SW, Kanyama C, Machado da Silva AL, Hakim JG, Kumarasamy N, Campbell TB, Hughes MD.

Open Forum Infect Dis. 2015 Jun 24;2(3):ofv095. doi: 10.1093/ofid/ofv095. eCollection 2015 Sep.

9.

Hematological and biochemical laboratory reference intervals for Zimbabwean adolescents.

Gomani P, Matubu AT, Mujuru HA, Munjoma MW, Tinago W, Mandozana G, Hakim JG, Gomo ZA, Chirenje ZM.

Clin Lab. 2015;61(1-2):101-11.

PMID:
25807644
10.

C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings.

Tenforde MW, Gupte N, Dowdy DW, Asmuth DM, Balagopal A, Pollard RB, Sugandhavesa P, Lama JR, Pillay S, Cardoso SW, Pawar J, Santos B, Riviere C, Mwelase N, Kanyama C, Kumwenda J, Hakim JG, Kumarasamy N, Bollinger R, Semba RD, Campbell TB, Gupta A; ACTG PEARLS and NWCS 319 Study Group.

PLoS One. 2015 Feb 26;10(2):e0117424. doi: 10.1371/journal.pone.0117424. eCollection 2015.

11.

Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).

Touzard Romo F, Smeaton LM, Campbell TB, Riviere C, Mngqibisa R, Nyirenda M, Supparatpinyo K, Kumarasamy N, Hakim JG, Flanigan TP.

HIV Clin Trials. 2014 Nov-Dec;15(6):246-60. doi: 10.1310/hct1506-246.

12.

Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.

Gomo ZA, Hakim JG, Walker SA, Tinago W, Mandozana G, Kityo C, Munderi P, Katabira E, Reid A, Gibb DM, Gilks CF; DART Team.

AIDS Res Ther. 2014 Oct 2;11(1):32. doi: 10.1186/1742-6405-11-32. eCollection 2014.

13.

Feasibility and sustainability of an interactive team-based learning method for medical education during a severe faculty shortage in Zimbabwe.

Gray J, Fana GT, Campbell TB, Hakim JG, Borok MZ, Aagaard EM.

BMC Med Educ. 2014 Mar 28;14:63. doi: 10.1186/1472-6920-14-63.

14.

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.

Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou SS, Anderson M, McCauley M, Gamble T, Kumarasamy N, Hakim JG, Kumwenda J, Pilotto JH, Godbole SV, Chariyalertsak S, de Melo MG, Mayer KH, Eshleman SH, Piwowar-Manning E, Makhema J, Mills LA, Panchia R, Sanne I, Gallant J, Hoffman I, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Havlir D, Cohen MS; HPTN 052-ACTG Study Team.

Lancet Infect Dis. 2014 Apr;14(4):281-90. doi: 10.1016/S1473-3099(13)70692-3. Epub 2014 Mar 4. Erratum in: Lancet Infect Dis. 2014 Apr;14(4):269.

15.

Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial.

Parikh SM, Obuku EA, Walker SA, Semeere AS, Auerbach BJ, Hakim JG, Mayanja-Kizza H, Mugyenyi PN, Salata RA, Kityo CM; DART Trial Team.

PLoS One. 2013 Oct 2;8(10):e76158. doi: 10.1371/journal.pone.0076158. eCollection 2013.

16.
17.

Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052).

Fogel JM, Wang L, Parsons TL, Ou SS, Piwowar-Manning E, Chen Y, Mudhune VO, Hosseinipour MC, Kumwenda J, Hakim JG, Chariyalertsak S, Panchia R, Sanne I, Kumarasamy N, Grinsztejn B, Makhema J, Pilotto J, Santos BR, Mayer KH, McCauley M, Gamble T, Bumpus NN, Hendrix CW, Cohen MS, Eshleman SH.

J Infect Dis. 2013 Nov 15;208(10):1624-8. doi: 10.1093/infdis/jit390. Epub 2013 Aug 1.

18.

Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.

Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG; PEARLS study team of the ACTG.

PLoS Med. 2012;9(8):e1001290. Epub 2012 Aug 14.

19.

Least among equals.

Kuritzkes DR, Hakim JG, Sanne I.

Clin Infect Dis. 2012 Mar;54(6):876-7. doi: 10.1093/cid/cir1048. No abstract available.

20.

Health Workforce Development with a Focus on CVD in Zimbabwe CHRIS Program, a Medical Education Partnership Initiative.

Hakim JG, Matenga JA, Havranek E, Koa D.

Glob Heart. 2011 Dec;6(4):219-20. doi: 10.1016/j.gheart.2011.07.001. Epub 2011 Aug 30. No abstract available.

Supplemental Content

Loading ...
Support Center